Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation
Interventions: DRUG: Carboplatin|DRUG: Eribulin|DRUG: Veliparib
Sponsor: The University of Texas Health Science Center at San Antonio